phands
Veteran Member
- Joined
- Jan 31, 2013
- Messages
- 1,976
- Location
- New York, Manhattan, Upper West Side
- Basic Beliefs
- Hardcore Atheist
If this works in humans.....
https://www.sciencealert.com/new-melanoma-cancer-vaccine-combo-is-100-effective-in-mice
[FONT="]A new cancer vaccine involving an immunotherapy drug and a chemical that boosts its efficacy has just shown a 100% success rate in treating melanoma in mice, according to a new study.[/FONT]
[FONT="][/FONT][FONT="]In an especially promising development, the researchers were even able to show their new therapy can fight cancer recurrence down the track, which could mean fewer relapses in the future.[/FONT]
[FONT="]"This co-therapy produced a complete response - a curative response - in the treatment of melanoma," says one of the researchers, Dale Boger, from the Scripps Research Institute in California.[/FONT]
[FONT="]"Just as a vaccine can train the body to fight off external pathogens, this vaccine trains the immune system to go after the tumour."[/FONT]
[FONT="]The researchers, from Scripps and the University of Texas Southwestern Medical Center, first screened around 100,000 compounds to look for one that could help them boost the effectiveness of a cancer immunotherapy drug.[/FONT]
[FONT="]Eventually they found a chemical called Diprovocim, which binds to an immune receptor in both humans and mice called Toll-like receptor; the next step was to start testing how this compound could aid the treatment of tumours in mice.[/FONT]
[FONT="]The researchers used a group of mice with an aggressive form of melanoma genetically engineered to contain ovalbumin, a common marker researchers can use to study immune responses in cancer, since it acts as an antigen - it triggers an immune response in the host. [/FONT]
[FONT="][/FONT][FONT="]All mice were given a cancer immunotherapy drug called anti-PD-L1, which is meant to prevent tumour cells from evading the host's immune system, and were then split into three groups of eight.[/FONT]
[FONT="]One group got only anti-PD-L1 and an injection of ovalbumin, the latter of which was meant to train their immune systems to recognise the tumour as an intruder.[/FONT]
[FONT="]A second group was given both of these, plus the chemical Diprovocim added to the ovalbumin injection, as a means to stimulate the immune system into action.[/FONT]
[FONT="]The third were also given both the anti-PD-L1 and the ovalbumin, but with the compound alum added instead of Diprovocim; alum also activates the immune system, but in a different way to Diprovocim.[/FONT]
[FONT="]Each animal was given two shots of the cocktail, the second seven days after the first. The injection was also not directly into the tumour, but away from the site - to see if immune cells could help the drugs travel to the tumour.[/FONT]
[FONT="]What the team found was that after the 54 day experiment the first group had a zero percent survival rate, the alum mice had a 25 percent survival rate, and the Diprovocim mice had a stunning 100 percent survival rate.[/FONT]
[FONT="][/FONT][FONT="]"It was exciting to see the vaccine working simultaneously with a cancer immunotherapy like anti-PD-L1," says Boger.[/FONT]
[FONT="]The team explains that the vaccine works by stimulating the immune system to make special cancer fighting cells called tumor-infiltrating leukocytes.[/FONT]
[FONT="]And the effects stuck around even after the cancer had gone.[/FONT]
https://www.sciencealert.com/new-melanoma-cancer-vaccine-combo-is-100-effective-in-mice